Back

Medscape, LLC

  • Incretins
  • Non-alcoholic Fatty Liver Disease

The Steatotic Liver Showdown: A Game Show on MASLD/MASH

The goal of this activity is for learners to be better able to incorporate evidence-based risk stratification and pharmacologic management strategies for patients with metabolic dysfunction-associated fatty liver disease (MAFLD)/MASH, including the use of incretin-based therapies where appropriate.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.75 credits

MOC types

ABIM — Medical KnowledgeUp to 0.75 points

FDA REMS

No

Qualifies for MIPS

No

Faculty 1

All faculty

Pricing

Free

Reported to ACCME by the provider

  • Enduring / On-demand
  • Credit · Up to 0.75 credits
  • MOC · Up to 0.75 points
  • Commercial Support
  • Released
    Nov 26, 2025
  • Last day to claim credit
    Nov 27, 2026 7 weeks left